Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06531772
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-29
Brief Title:
Characteristics and Outcomes of TB and HIV Co-infections
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Characteristics and Outcomes of TB and HIV Co-infections
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
People Living with HIV PLHIV are prone to several opportunistic infections depending on the degree of immunosuppression as well as infections prevalent in their geographic areacountry These include a wide variety of mycobacterial diseases fungal infections bacterial pneumonias pneumocystis jirovecii pneumonia cryptococcal infections toxoplasmosis etc
Tuberculosis remains the most common opportunistic infection in the developing countries like South Africa and India
HIV and tuberculosis TB are two of the most challenging infections faced by the humanity HIV is the most important risk factor for progression of latent Mycobacterium tuberculosis MTB to active disease The most common cause of death among PLHIV is tuberculosis These two infections place immense burden on health care systems worldwide During the last two decades sustained research and public health initiatives on prevention and therapeutic advances have allayed morbidity and mortality due to HIV and TB to a large extent however more needs to be done
Globally an estimated 10 million people fell ill with TB and an estimated 14 million people died of TB in 2018 12 million among HIV negative and 251 000 among HIV positive people There were around 379 million PLHIV worldwide in 2018
In the pre-antiretroviral therapy ART era nearly one-third of HIVAIDS acquired immune deficiency syndrome related deaths were due to TB Wider availability of ART has reduced the mortality of HIV-associated TB significantly but it still remains high compared to HIV-uninfected individuals The mortality risk with HIV TB coinfection accounts for approximately 25 of global HIVAIDS deaths every year
This study aims to investigate characteristics and outcomes of TB and HIV co-infections in Upper Egypt
Tuberculosis remains the most common opportunistic infection in the developing countries like South Africa and India
HIV and tuberculosis TB are two of the most challenging infections faced by the humanity HIV is the most important risk factor for progression of latent Mycobacterium tuberculosis MTB to active disease The most common cause of death among PLHIV is tuberculosis These two infections place immense burden on health care systems worldwide During the last two decades sustained research and public health initiatives on prevention and therapeutic advances have allayed morbidity and mortality due to HIV and TB to a large extent however more needs to be done
Globally an estimated 10 million people fell ill with TB and an estimated 14 million people died of TB in 2018 12 million among HIV negative and 251 000 among HIV positive people There were around 379 million PLHIV worldwide in 2018
In the pre-antiretroviral therapy ART era nearly one-third of HIVAIDS acquired immune deficiency syndrome related deaths were due to TB Wider availability of ART has reduced the mortality of HIV-associated TB significantly but it still remains high compared to HIV-uninfected individuals The mortality risk with HIV TB coinfection accounts for approximately 25 of global HIVAIDS deaths every year
This study aims to investigate characteristics and outcomes of TB and HIV co-infections in Upper Egypt
Detailed Description:
People Living with HIV PLHIV are prone to several opportunistic infections depending on the degree of immunosuppression as well as infections prevalent in their geographic areacountry These include a wide variety of mycobacterial diseases fungal infections bacterial pneumonias pneumocystis jirovecii pneumonia cryptococcal infections toxoplasmosis etc
Tuberculosis remains the most common opportunistic infection in the developing countries like South Africa and India
HIV and tuberculosis TB are two of the most challenging infections faced by the humanity HIV is the most important risk factor for progression of latent Mycobacterium tuberculosis MTB to active disease The most common cause of death among PLHIV is tuberculosis These two infections place immense burden on health care systems worldwide During the last two decades sustained research and public health initiatives on prevention and therapeutic advances have allayed morbidity and mortality due to HIV and TB to a large extent however more needs to be done
Globally an estimated 10 million people fell ill with TB and an estimated 14 million people died of TB in 2018 12 million among HIV negative and 251 000 among HIV positive people There were around 379 million PLHIV worldwide in 2018
In the pre-antiretroviral therapy ART era nearly one-third of HIVAIDS acquired immune deficiency syndrome related deaths were due to TB Wider availability of ART has reduced the mortality of HIV-associated TB significantly but it still remains high compared to HIV-uninfected individuals The mortality risk with HIV TB coinfection accounts for approximately 25 of global HIVAIDS deaths every year
This study aims to investigate characteristics and outcomes of TB and HIV co-infections in Upper Egypt
Tuberculosis remains the most common opportunistic infection in the developing countries like South Africa and India
HIV and tuberculosis TB are two of the most challenging infections faced by the humanity HIV is the most important risk factor for progression of latent Mycobacterium tuberculosis MTB to active disease The most common cause of death among PLHIV is tuberculosis These two infections place immense burden on health care systems worldwide During the last two decades sustained research and public health initiatives on prevention and therapeutic advances have allayed morbidity and mortality due to HIV and TB to a large extent however more needs to be done
Globally an estimated 10 million people fell ill with TB and an estimated 14 million people died of TB in 2018 12 million among HIV negative and 251 000 among HIV positive people There were around 379 million PLHIV worldwide in 2018
In the pre-antiretroviral therapy ART era nearly one-third of HIVAIDS acquired immune deficiency syndrome related deaths were due to TB Wider availability of ART has reduced the mortality of HIV-associated TB significantly but it still remains high compared to HIV-uninfected individuals The mortality risk with HIV TB coinfection accounts for approximately 25 of global HIVAIDS deaths every year
This study aims to investigate characteristics and outcomes of TB and HIV co-infections in Upper Egypt
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None